For Patients With mCRPC, Results With Pluvicto in Real-World Settings Keep Pace With Clinical Trials
Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after one ARPI and delayed chemotherapy.
Despite these declines, CRC incidence is rising in adults younger than 65, increasing by 3% per year among patients aged 20 to 49 years and 0.4% per year among those aged 50 to 64 years. Consequently, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results